rethinkPeptides Search
Menu
Research citation

Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial.

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial.

EClinicalMedicine, 72, 102624

Citation

Hansen, Morten S; Wölfel, Eva M; Jeromdesella, Shakespeare; Møller, Jens-Jakob K; Ejersted, Charlotte; Jørgensen, Niklas R; Eastell, Richard; Hansen, Stinus G; Frost, Morten. (2024). Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial.. EClinicalMedicine, 72, 102624. https://doi.org/10.1016/j.eclinm.2024.102624